Aclaris Therapeutics Valuation
| ACRS Stock | USD 3.96 0.11 2.70% |
At this time, the firm appears to be undervalued. Aclaris Therapeutics shows a prevailing Real Value of $10.32 per share. The current price of the firm is $3.96. Our model approximates the value of Aclaris Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.26, profit margin of (1.37) %, and Current Valuation of 172.04 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Aclaris Therapeutics' valuation include:
Price Book 2.2337 | Enterprise Value 172 M | Enterprise Value Ebitda 0.2785 | Price Sales 10.7361 | Enterprise Value Revenue 6.3534 |
Undervalued
Today
Please note that Aclaris Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of Aclaris Therapeutics is based on 3 months time horizon. Increasing Aclaris Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Aclaris stock is determined by what a typical buyer is willing to pay for full or partial control of Aclaris Therapeutics. Since Aclaris Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aclaris Stock. However, Aclaris Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.96 | Real 10.32 | Target 30.0 | Hype 5.25 | Naive 4.08 |
The intrinsic value of Aclaris Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Aclaris Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Aclaris Therapeutics helps investors to forecast how Aclaris stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aclaris Therapeutics more accurately as focusing exclusively on Aclaris Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Aclaris Therapeutics' intrinsic value based on its ongoing forecasts of Aclaris Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Aclaris Therapeutics' closest peers.
Aclaris Therapeutics Cash |
|
Aclaris Valuation Trend
Aclaris Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Aclaris Therapeutics' financial worth over time. Using both Aclaris Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Aclaris Revenue by Product
Aclaris Therapeutics Total Value Analysis
Aclaris Therapeutics is presently projected to have valuation of 172.04 M with market capitalization of 290.72 M, debt of 426 K, and cash on hands of 248.6 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Aclaris Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
172.04 M | 290.72 M | 426 K | 248.6 M |
Aclaris Therapeutics Investor Information
About 90.0% of the company shares are held by institutions such as insurance companies. The book value of Aclaris Therapeutics was presently reported as 1.82. The company recorded a loss per share of 0.52. Aclaris Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Aclaris Therapeutics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Aclaris Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Aclaris Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aclaris Therapeutics has an asset utilization ratio of 15.83 percent. This implies that the Company is making $0.16 for each dollar of assets. An increasing asset utilization means that Aclaris Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Aclaris Therapeutics Ownership Allocation
Aclaris Therapeutics holds a total of 71.43 Million outstanding shares. The majority of Aclaris Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aclaris Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aclaris Therapeutics. Please pay attention to any change in the institutional holdings of Aclaris Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Aclaris Therapeutics Profitability Analysis
The company reported the previous year's revenue of 31.25 M. Net Loss for the year was (88.48 M) with loss before overhead, payroll, taxes, and interest of (60.02 M).About Aclaris Therapeutics Valuation
The stock valuation mechanism determines Aclaris Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Aclaris Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aclaris Therapeutics. We calculate exposure to Aclaris Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aclaris Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 13.2 M | 13.8 M | |
| Pretax Profit Margin | (2.84) | (2.99) | |
| Operating Profit Margin | (3.12) | (3.27) | |
| Net Loss | (2.83) | (2.97) | |
| Gross Profit Margin | 0.42 | 0.25 |
Aclaris Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Aclaris Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 69.8 M |
Aclaris Therapeutics Current Valuation Indicators
Aclaris Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Aclaris Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Aclaris Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Aclaris Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Aclaris Therapeutics' worth.Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.